Dr. Tricia Cottrell is a clinician scientist whose research focuses on tumour-immune interactions in solid tumours, and the identification of predictive and prognostic biomarkers in pre-treatment and post-treatment tumour tissues. Cottrell completed her MD, PhD, Anatomic Pathology Residency, and postdoctoral training at Johns Hopkins University School of Medicine and is now an Assistant Professor in the Department of Pathology and Molecular Medicine at Queen’s University.
Some of Dr. Cottrell’s research contributions include the first characterization of the features of immune-mediated tumour regression following neoadjuvant anti-PD-1 therapy in non-small cell lung carcinoma. This first published clinical trial was used to develop a set of proposed immune-related pathologic response criteria for the standardized and reproducible assessment of pathologic response following neoadjuvant immunotherapy. These criteria are now being evaluated in a large clinical trial of neoadjuvant anti-PD-1 therapy in non-small cell lung carcinoma. These findings have also been extended to other tumor types and efforts to develop a pan-cancer method for quantifying pathologic response are underway.
Dr. Cottrell is Senior Investigator in the Canadian Cancer Trials Group (CCTG) in Kingston and the Deputy Director of CCTG’s Tumour Tissue and Data Repository.
- Postdoctoral Fellow, Johns Hopkins University School of Medicine
- Anatomic Pathology Resident, Johns Hopkins Hospital
- MD/PhD, Johns Hopkins University School of Medicine
- Clinician Scientist I, OICR
- Assistant Professor, Department of Pathology and Molecular Medicine, Queen’s University
- Senior Investigator, Laboratory Translational Research, Canadian Cancer Trials Group
- Deputy Director, Canadian Cancer Trails Group Tumour Tissue and Data Repository
- Member, Canadian Cancer Trials Group Correlative Science and Tumour Biology Committee Executive
- Stein JE, Soni A, Danilova L, Cottrell TR, …, Taube JM. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019; 30(4):589-596.
- Forde PM, Chafte JE, Smith KN, …, Cottrell TR, …, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986.
- Cottrell TR, Thompson ED, Forde PM, …, Taube JM. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018; 29(8):1853-1860.
- Cottrell TR, Duong AT, Gocke CD, …, Belchis DA. PD-L1 expression in inflammatory myofibroblastic tumors. Mod Pathol. 2018; 31(7):1155-1163.
- Yanik EL, Kaunitz GJ, Cottrell TR, …, Taube JM. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. JAMA Oncol. 2017; 3(7):974-978.
To collaborate with Dr. Cottrell, please contact her directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.